Bruker Corporation (BRKR)vsNovartis AG ADR (NVS)
BRKR
Bruker Corporation
$44.16
+0.98%
HEALTHCARE · Cap: $6.44B
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1546% more annual revenue ($56.58B vs $3.44B). NVS leads profitability with a 23.9% profit margin vs -0.3%. BRKR appears more attractively valued with a PEG of 1.52. NVS earns a higher WallStSmart Score of 51/100 (C-).
BRKR
Hold42
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.9%
Fair Value
$58.89
Current Price
$44.16
$14.73 discount
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
ROE of -0.4% — below average capital efficiency
Revenue declined 0.2%
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BRKR
The strongest argument for BRKR centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : BRKR
The primary concerns for BRKR are PEG Ratio, Piotroski F-Score, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BRKR profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
BRKR carries more volatility with a beta of 1.12 — expect wider price swings.
BRKR is growing revenue faster at -0.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 42/100), backed by strong 23.9% margins. BRKR offers better value entry with a 27.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bruker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?